RedHill Biopharma Profile

4.96
USD 0.14  2.90%
8%
26%

RedHill Biopharma Summary

RedHill Biopharma Ltd (RDHL) is traded on Nasdaq Capital Markets in USA. It is located in ISRAEL and employs 74 people. RedHill Biopharma is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 101.83 M. RedHill Biopharma Ltd conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 171.68 M outstanding shares of which 809.46 K shares are at this time shorted by private and institutional investors with about 3.39 trading days to cover. Redhill Biopharma currently holds about 46.2 M in cash with (44.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.17.
Check RedHill Biopharma Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Below OddsHorizonTargetAbove Odds
about 15.09%30 days 4.96  about 84.82%
Based on normal probability distribution, the odds of RedHill Biopharma to move above current price in 30 days from now is about 84.82% (This RedHill Biopharma Ltd probability density function shows the probability of RedHill Biopharma Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Creative PlanningCommon Shares140.4 K723 K
Private Bank Trust CoCommon Shares20 K103 K
View RedHill Biopharma Diagnostics

Selected RedHill Biopharma Ltd Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

RedHill Biopharma Against Markets

Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
< 48% 
Equity ratings for RedHill Biopharma Ltd are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, and in-licensedacquired drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company was founded in 2009 and is headquartered in Tel Aviv, Israel. RedHill Biopharma operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 74 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameRedHill Biopharma Ltd
CEOOri ShiloView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
LocationISRAEL
Business Address21 Ha'arba'a Street
Foreign Associate  Israel
ExchangeNasdaq Capital Markets
CUSIP757468103
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.redhillbio.com
Contact Number972 3 541 3131
CurrencyUSD - US Dollar

Recommendations

RedHill Biopharma Analyst Recommendations
Target PriceAdvice# of Analysts
31.67Strong Buy3Odds
RedHill Biopharma Ltd current and past analyst recommendations published by number of research institutions as well as average analyst consensus
RedHill Biopharma Analyst Advice  

Earnings

RedHill Biopharma Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.63February 23, 2017
RedHill Biopharma Ltd normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  

Directors

RedHill Biopharma Corporate Directors
Ofer Tsimchi Director
Shmuel Cabilly Director
Kenneth Reed Director, Ph.D
Additionally take a look at Your Equity Center. Please also try Crypto Portfolio Optimizer module to optimize portfolio of digital coins and token across multiple currency and exchanges.